Skip to main content
HHS Author Manuscripts logoLink to HHS Author Manuscripts
. Author manuscript; available in PMC: 2018 Aug 7.
Published in final edited form as: Ann Epidemiol. 2018 Mar 6;28(5):328–330. doi: 10.1016/j.annepidem.2018.03.001

Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014

Jun Li a,*, David A Siegel a,b, Jessica B King c
PMCID: PMC6080305  NIHMSID: NIHMS982729  PMID: 29678312

Abstract

Purpose:

Current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data.

Methods:

Data on prostate cancer cases came from the 2004—2014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC).

Results:

We identified 2,137,054 incident prostate cancers diagnosed during 2004—2014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004—2010 (APC = −1.2) and increased during 2010—2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65—74 and older than or equal to 85 years, in men with white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5).

Conclusions:

Using data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010—2014 among men in certain ages, in white, and with non-Hispanic ethnicity.

Keywords: Prostate cancer, Cancer incidence, Cancer stage

Background

With the introduction of prostate-specific antigen (PSA) testing in the mid-1980s, the incidence rate of distant-stage prostate cancer has decreased more than 60% during the last two decades [1]. Concluding that harms from PSA-based screening outweighed benefits, the United States Preventive Services Task Force recommended against routine PSA-based screening for men older than or equal to 75 years of age in 2008 and all ages in 2012 [2]. Studies have consistently shown that PSA testing prevalence and localized/regional prostate cancer incidence rates declined following these recommendations [36]. However, current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence. These differences might be because of low population coverage (≤28%) and wide age groupings [3,7,8].

Objective

To examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data.

Methods and findings

Data on prostate cancer cases came from the United States Cancer Statistics (USCS) data set, which includes the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results (SEER) programs. Incidence data for all registries except Nevada met USCS publication criteria (http://www.cdc.gov/cancer/npcr/standards.htm) during 2004—2014, and represented 99.1% of the U.S. population. We identified prostate cancer cases using the International Classification of Diseases for Oncology, Third Edition site code C619 and behavior code 3. We excluded 1160 autopsy or death certificate-only cases (0.05%) and 72,232 nonmicroscopically confirmed cases (3.27%). We calculated stage-specific (localized, regional, distant, and unstaged) incidence and 95% confidence intervals by age (5-year age grouping), race (white, black, Asian/Pacific Islander, and American Indian/Alaska Native), and ethnicity (Hispanic and non-Hispanic) using SEER*Stat. Rates for all variables except age were age standardized to the 2000 U.S. standard population. To measure the changes in rates over time, we calculated annual percentage change (APC) using Joinpoint regression software. A maximum of two join points were used to determine a change of direction in trends during our study period. APCs were considered to be statistically significant if P <.05.

We identified 2,137,054 incident prostate cancers diagnosed during 2004—2014. The age-adjusted incidence rate was 453.8 per 100,000. Of these cases, 80% were localized, 10% were regional, 4% were distant, and 5% were unstaged (data not shown). Table 1 shows cancer stage-specific incidence rates and trends by age, race, and ethnicity. For localized- and regional-stage prostate cancers, incidence rates were stable during 2004—2007 and significantly declined during 2007—2014. In contrast, distant-stage prostate cancer incidence significantly decreased during 2004—2010 (APC = −1.2) and increased during 2010—2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65—74 and older than or equal to 85 years, and in men with white race (APC = 3.9), or non-Hispanic ethnicity (APC = 3.5).

Table 1.

Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004—2014

Characteristics Count Rate* 95% CI Years APC1 95% CI Years APC2 95% CI
Total 2,137,054 453.8 453.2—454.4 2004—2007 3.7 −3.7 to 11.7 2007—2014 −7.5 −9.3 to −5.6
Stage
    Localized 1,708,064 362.5 361.9—363.0 2004—2007 4.3 −3.8 to 13.1 2007—2014 −8.6 − 10.6 to −6.6
    Regional 233,245 46.3 46.1—46.5 2004—2007 2.9 −4.1 to 10.5 2007—2014 −3.2 −5.0 to ∑1.3
    Distant 84,954 19.5 19.4—19.7 2004—2010 − 1.2 −2.0 to −0.3 2010—2014 3.3 1.6 to 5.0
    Unstaged 110,791 25.5 25.3—25.6 2004—2014 −4.4 −6.1 to −2.6
Localized
    Age
        50—54 years 126,885 109.9 109.3—110.5 2004—2009 3.4 −0.2 to 7.2 2009—2014 −8.9 −12.1 to −5.6
        55—59 years 240,578 235.4 234.5—236.3 2004—2008 3.5 −0.9 to 8.0 2008—2014 −8.1 −10.2 to −5.9
        60—64 years 327,540 394.7 393.4—396.1 2004—2007 6.3 − 1.9 to 15.2 2007—2014 −7.8 −9.7 to −5.8
        65—69 years 373,529 594.2 592.3—596.1 2004—2007 5.3 −3.9 to 15.3 2007—2014 −7.8 −10.0 to −5.5
        70—74 years 300,278 643.9 641.6—646.2 2004—2007 4.1 −4.3 to 13.3 2007—2014 −8.9 −11.0 to −6.9
        75—79 years 202,941 575.0 572.5—577.5 2004—2007 2.6 −5.7 to 11.6 2007—2014 −10.1 −12.1 to −8.1
        80—84 years 95,107 384.3 381.8—386.7 2004—2007 −0.6 −9.0 to 8.7 2007—2014 −11.6 −13.7 to −9.5
        85 + years 41,206 216.7 214.7—218.8 2004—2007 −2.8 − 10.6 to 5.6 2007—2014 −13.2 −15.2 to −11.3
    Race
        White 1,380,775 341.5 340.9—342.0 2004—2007 4.3 −4.0 to 13.4 2007—2014 −9.1 −11.1 to −7.1
        Black 244,065 544.0 541.8—546.3 2004—2008 1.5 −2.2 to 5.2 2008—2014 −7.8 −9.6 to −6.0
        API 6296 181.5 176.6—186.4 2004—2009 −2.2 −5.6 to 1.3 2009—2014 −11.7 −14.7 to −8.5
        AIAN 32,356 182.6 180.5—184.6 2004—2011 −5.1 −7.5 to —2.6 2011—2014 −15.0 −22.8 to −6.4
    Ethnicity
        Non-Hispanic 1,605,664 368.7 368.1—369.2 2004—2007 4.5 −3.8 to 13.5 2007—2014 −8.6 −10.6 to −6.5
        Hispanic 102,161 293.6 291.7—295.5 2004—2008 0.0 −3.2 to 3.3 2008—2014 −9.4 −10.9 to −7.8
Regional
    Age
        50—54 years 24,586 21.3 21.0—21.6 2004—2009 0.9 −2.9 to 4.8 2009—2014 −6.0 −9.5 to −2.3
        55—59 years 44,333 43.4 43.0—43.8 2004—2010 −0.6 −3.5 to 2.3 2010—2014 −5.7 −10.7 to −0.4
        60—64 years 57,258 69.0 68.4—69.6 2004—2007 3.3 −4.2 to 11.3 2007—2014 −4.1 −6.0 to −2.1
        65—69 years 56,593 90.0 89.3—90.8 2004—2010 1.0 − 1.6 to 3.7 2010—2014 −5.7 −10.3 to −1.0
        70—74 years 30,332 65.0 64.3—65.8 2004—2007 4.4 −2.2 to 11.5 2007—2014 −1.5 −3.2 to 0.2
        75—79 years 11,651 33.0 32.4—33.6 2004—2014 −0.8 − 1.8 to 0.3
        80—84 years 5146 20.8 20.2—21.4 2004—2014 −2.7 −4.3 to −1.1
        85 + years 3346 17.6 17.0—18.2 2004—2014 −3.7 −5.2 to −2.2
    Race
        White 196,138 45.7 45.5—45.9 2004—2007 3.0 −4.2 to 10.9 2007—2014 −3.3 −5.1 to −1.4
        Black 28,288 56.3 55.6—57.0 2004—2014 −1.6 −2.6 to −0.5
        API 947 23.2 21.6—24.8 2004—2014 −3.2 −5.9 to −0.4
        AIAN 5280 26.7 25.9—27.4 2004—2011 1.0 −2.0 to 4.1 2011—2014 −9.5 −19.1 to 1.2
    Ethnicity
        Non-Hispanic 218,892 47.2 47.0—47.5 2004—2007 3.1 −4.1 to 10.9 2007—2014 −3.1 −5.0 to −1.2
        Hispanic 14,336 36.5 35.8—37.1 2004—2014 −2.1 −3.0 to −1.2
Distant
    Age
        50—54 years 4480 3.9 3.8—4.0 2004—2014 2.0* 0.9 to 3.0
        55—59 years 8484 8.3 I 2004—2014 2.8* 1.5 to 4.1
        60—64 years 11,898 14.3 14.1—14.6 2004—2008 −2.1 −5.9 to 1.9 2008—2014 3.5 1.3 to 5.7
        65—69 years 13,310 21.2 20.8—21.5 2004—2014 −0.4 − 1.5 to 0.7
        70—74 years 12,847 27.5 27.1—28.0 2004—2008 −2.1 −5.6 to 1.5 2008—2014 1.9 0.0 to 3.9
        75—79 years 12,405 35.1 34.5—35.8 2004—2011 −1.4* −2.4 to —0.4 2011—2014 5.1 1.2 to 9.1
        80—84 years 11,372 45.9 45.1—46.8 2004—2010 −2.4* −4.4 to —0.2 2010—2014 4.2 0.1 to 8.5
        85 + years 10,158 53.4 52.4—54.5 2004—2014 −0.5 − 1.7 to 0.8
    Race
        White 65,709 17.5 17.4—17.7 2004—2010 −0.8 − 1.8 to 0.1 2010—2014 3.9 2.1 to 5.7
        Black 16,062 41.1 40.4—41.8 2004—2010 −3.3* −4.9 to −1.8 2010—2014 0.3 −2.6 to 3.4
        API 476 15.8 14.2—17.4 2004—2014 −0.4 −3.3 to 2.6
        AIAN 2005 12.6 12.0—13.2 2004—2014 −1.2 −3.2 to 0.8
    Ethnicity
        Non-Hispanic 78,399 19.4 19.3—19.6 2004—2010 −1.1* − 1.9 to −0.3 2010—2014 3.5 1.9 to 5.1
        Hispanic 6553 20.9 20.4—21.5 2004—2011 −2.9* −3.9 to −1.9 2011—2014 2.9 −1.0 to 7.0
Unstaged
    Age
        50—54 years 4555 3.9 3.8—4.1 2004—2014 0.7 − 1.5 to 3.0
        55–59 years 9477 9.3 9.1 —9.5 2004—2014 1.0 −0.8 to 2.9
        60–64 years 15,082 18.2 17.9—18.5 2004—2009 3.3 − 1.5 to 8.2 2009—2014 −3.9 −8.3 to 0.8
        65–69 years 19,879 31.6 31.2—32.1 2004—2014 −1.1 −3.4 to 1.1
        70–74 years 20,362 43.7 43.1—44.3 2004—2010 0.4 −4.6 to 5.6 2010—2014 −9.4 −17.6 to −0.5
        75–79 years 18,539 52.5 51.8—53.3 2004—2007 1.9 −9.5 to 14.8 2007—2014 −7.9 −10.8 to −4.9
        80—84 years 13,162 53.2 52.3—54.1 2004—2007 −2.0 − 11.8 to 9.0 2007—2014 −10.9 −13.4 to −8.3
        85 + years 9735 51.2 50.2—52.2 2004—2007 −3.6 −13.1 to 7.0 2007—2014 −12.9 −15.3 to −10.4
    Race
        White 76,699 20.5 20.3—20.6 2004—2014 −7.0* −8.9 to −5.2
        Black 14,995 39.2 38.5—39.9 2004—2014 −5.0* −6.6 to −3.3
        API 587 20.9 19.1—22.9 2004—2014 −4.6* −7.4 to −1.6
        AIAN 2341 15.0 14.4—15.7 2004—2010 6.3 −0.2 to 13.4 2010—2014 −9.3 −19.5 to 2.2
    Ethnicity
        Non-Hispanic 100,599 24.9 24.7– 25.0 2004–2014 −4.4 −6.1 to −2.7
        Hispanic 9975 33.5 32.8– 34.2 2004–2009 5.0 −3.7 to 14.5 2009–2014 − 12.3 −19.6 to −4.3

APC = Annual Percentage Change; API = Asian or Pacific Islander; AIAN = American Indian/Alaska Native; Cl = confidence interval.

*

Rates are per 100,000 and rates for all variables except age are age-adjusted to the 2000 U.S. Standard Population (19 age groups—Census P25–1130).

Trends were measured with annual percentage change in rates and were considered to increase or decrease if P < .05; otherwise trends were considered stable.

P < .05.

CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program.

Discussion

Using data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010—2014 among men aged older than or equal to 50 years. Stratified analyses by age, race, and ethnicity suggest that this increase occurred among men of white race, non-Hispanic ethnicity, and men aged 50—64 and 75—84 years.

Two previously published SEER studies showed stable trends of distant-stage prostate cancer among men aged less than 75 years [3,5]. However, three other SEER studies reported increasing trends among men aged 45—64, 50—69, and 45—69 years, respectively [7,9,10]. Past studies reported either increasing or decreasing trends for men aged older than or equal to 75 years [5,8,9]. These studies were smaller and did not include the 2014 cancer incidence data. Using the 2004—2014 USCS data, we found a significant increase in distant-stage prostate cancer incidence among men aged 50—64 and 75—84 years. A significant increase was also observed among white men, which confirms findings reported by Dalela et al. [9] Despite the differences in prostate cancer screening recommendations among major medical organizations [2,11,12], studies have shown that prostate cancer incidence and PSA-based screening rates declined after the United States Preventive Services Task Force issued the “D” recommendations for prostate cancer screening in 2012 [35]. Because of the long natural history of prostate cancer and only two additional years’ cancer incidence data after 2012 available for analysis, long-term studies are needed to discern increased rates of distant cancer were a result of decreased screening. These studies will help to inform the development of future prostate cancer screening recommendations.

This study has at least five limitations. First, full case ascertainment may impede timely reporting of prostate cancer cases; however, delayed reporting likely caused underestimation of rates and increasing trends in the recent years. Second, trend analyses, a function of time, may be affected by outliers in a given year. Third, only two years of incidence data after 2012 were available for analysis. Fourth, Joinpoint models choose the best fit segmented line with the smallest number of join points through several years of data. The pattern of the trend is sensitive to the number and location of join point and may partially contribute to differences in trends from previous studies. Last, we did not examine Gleason scores because they are not currently available in the USCS data set.

Footnotes

Disclosure: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

No financial conflict of interest for all authors and no funding sources claimed.

References

  • [1].Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER cancer statistics review, 1975—2014. Bethesda, MD: National Cancer Institute; 2017. https://seer.cancer.gov/csr/1975_2014. [Accessed 10 September 2017]. [Google Scholar]
  • [2].Moyer VA, U.S. Preventive Service Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157(2):120–34. [DOI] [PubMed] [Google Scholar]
  • [3].Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force Recommendations Against Screening.JAMA Oncol 2016;2(12):1657–60. [DOI] [PubMed] [Google Scholar]
  • [4].Li J, Berkowitz Z, Hall IJ. Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations. J Am Board Fam Med 2015;28(4):491–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314(19):2054–61. [DOI] [PubMed] [Google Scholar]
  • [6].Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med 2012;172(16):1267–8. [DOI] [PubMed] [Google Scholar]
  • [7].Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, et al. Trends in United States prostate cancer incidence rates by age and stage, 1995–2012. Cancer Epidemiol Biomarkers Prev 2016;25(2):259–63. [DOI] [PubMed] [Google Scholar]
  • [8].Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol 2017;3(5):705–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Dalela D, Sun M, Diaz M, Karabon P, Seisen T, Trinh QD, et al. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. Eur Urol Focus May 12 2017;S2405–4569(17): 30118–9. [DOI] [PubMed] [Google Scholar]
  • [10].Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Eur Urol Focus November 18 2017;S2405–4569(17):30254–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013;190(2):419–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63(2):88–105. [DOI] [PubMed] [Google Scholar]

RESOURCES